Skip to content
PeptideAgent

Adipotide regulatory status

Current status of Adipotide in the United States: Unscheduled. In sport: WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What is the current status of Adipotide?

Regulatory: UnscheduledWADA: WADA prohibitedVerified: Verified Sep 22, 2026
FDA and compounding
Not FDA approved and not on any FDA compounding list as of the pages current to April 2026. Adipotide has never been nominated for the 503A bulks list and has no USP monograph, so no compounding pharmacy has a lawful basis to dispense it. It remains an investigational compound with unpublished phase 1 results.
WADA
WADA prohibited
Access path
  1. No lawful United States access path identified on the last verified date outside a registered clinical trial. Clinical development stopped after phase 1.
  2. Not available as an FDA approved product and not eligible for compounding under section 503A or 503B.
  3. Products labeled research use only are not lawful for human use and are not verified for identity or purity.

Full Adipotide page: evidence, dosing in the literature, and sources

How has the status of Adipotide changed over time?

No dated regulatory event has been recorded for Adipotide. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for Adipotide and the source of each dated event.

  1. [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
  2. [2]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026
  3. [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026